All In Biotech

Drug Trial Radar · NCT07574047

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. A Phase II Trial.

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Oct 12, 2026

Primary completion

Jun 2030

Study completion Jun 2032

Sponsor

Lead sponsor
Swiss Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Melanoma remains a common cancer with rising incidence, and despite significant improvements with immune checkpoint inhibitors (ICIs), clinical outcomes remain heterogeneous. Retrospective analyses across multiple tumor types, including melanoma, suggest that earlier daytime administration of ICIs may enhance therapeutic effectiveness, potentially due to circadian modulation of immune function. A pronounced survival benefit has been observed particularly among female patients receiving earlier infusions. This trial prospectively evaluates whether aligning ICI administration with circadian immune activity can improve outcomes in melanoma and support the development of sex-specific optimization of immunotherapy.

Conditions

  • Melanoma
  • Advanced Melanoma

Interventions

  • Immune Checkpoint InhibitorsDrug

    Morning administration of ICI per physician's choice, according to local practice: Nivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W) Pembrolizumab (Keytruda®) Monotherapy \- 200 mg administered intravenously every 3 weeks (Q3W) Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy * Induction Phase: * Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W) * Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W) * Administered for 4 cycles * Maintenance Phase: * Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)

  • Immune Checkpoint InhibitorsDrug

    Afternooon administration of ICI per physician's choice, according to local practice: Nivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W) Pembrolizumab (Keytruda®) Monotherapy \- 200 mg administered intravenously every 3 weeks (Q3W) Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy * Induction Phase: * Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W) * Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W) * Administered for 4 cycles * Maintenance Phase: * Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From randomization to Progressive Desease or death, up to 6 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Universitätsspital Basel

    Basel, Switzerland · Recruiting

  • Ente Ospedaliero Cantonale (EOC)

    Bellinzona, Switzerland · Recruiting

  • Inselspital, Bern

    Bern, Switzerland · Recruiting

  • Hôpitaux Universitaires de Genève HUG

    Geneva, Switzerland · Recruiting

  • Centre Hospitalier Universitaire Vaudois (CHUV)

    Lausanne, Switzerland · Recruiting

  • Spital Thurgau (Kantonsspital Münserlingen und Frauenfeld)

    Münsterlingen, Switzerland · Recruiting

  • HOCH Health Ostschweiz - Kantonsspital St. Gallen

    Sankt Gallen, Switzerland · Recruiting

  • Universitätsspital Zürich USZ

    Zurich, Switzerland · Recruiting

  • HFR Fribourg

    Fribourg, Canton of Fribourg, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.